Inactivation of the CYLD Deubiquitinase by HPV E6 Mediates Hypoxia-Induced NF-κB Activation

Cancer Cell

Volumn 14, Issue 5, 2008, Pages 394-407

  An, Jiabin ^a   Mo, Deqiong ^a   Liu, Huiren ^a   Veena, Mysore S ^a   Srivatsan, Eri S ^a   Massoumi, Ramin ^b   Rettig, Matthew B ^a,c  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CELLCYCLE; SIGNALING

Indexed keywords

CYLD DEUBIQUITINASE; ENZYME; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYSINE DERIVATIVE; PROTEASOME; PROTEIN E6; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; EMBRYO; ENZYME DEGRADATION; ENZYME INACTIVATION; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HYPOXIA; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEROTYPE; UBIQUITINATION; UTERINE CERVIX CARCINOMA; VIRUS INFECTION; WART VIRUS;

HUMAN PAPILLOMAVIRUS;

EID: 54549103311     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2008.10.007     Document Type: Article

References (53)

1. Baldwin A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J. Clin. Invest. 107 (2001) 241-246
2. Basseres D.S., and Baldwin A.S. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25 (2006) 6817-6830
3. Brummelkamp T.R., Nijman S.M., Dirac A.M., and Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 424 (2003) 797-801
4. Butz K., Ristriani T., Hengstermann A., Denk C., Scheffner M., and Hoppe-Seyler F. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 22 (2003) 5938-5945
5. Chen Z.J. Ubiquitin signalling in the NF-kappaB pathway. Nat. Cell Biol. 7 (2005) 758-765
6. Cockman M.E., Lancaster D.E., Stolze I.P., Hewitson K.S., McDonough M.A., Coleman M.L., Coles C.H., Yu X., Hay R.T., Ley S.C., et al. Posttranslational hydroxylation of ankyrin repeats in IkappaB proteins by the hypoxia-inducible factor (HIF) asparaginyl hydroxylase, factor inhibiting HIF (FIH). Proc. Natl. Acad. Sci. USA 103 (2006) 14767-14772
7. Cummins E.P., Berra E., Comerford K.M., Ginouves A., Fitzgerald K.T., Seeballuck F., Godson C., Nielsen J.E., Moynagh P., Pouyssegur J., et al. Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc. Natl. Acad. Sci. USA 103 (2006) 18154-18159
8. Denko N.C., Fontana L.A., Hudson K.M., Sutphin P.D., Raychaudhuri S., Altman R., and Giaccia A.J. Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 22 (2003) 5907-5914
9. Ellenson L.H., and Wu T.C. Focus on endometrial and cervical cancer. Cancer Cell 5 (2004) 533-538
10. Favre-Bonvin A., Reynaud C., Kretz-Remy C., and Jalinot P. Human papillomavirus type 18 E6 protein binds the cellular PDZ protein TIP-2/GIPC, which is involved in transforming growth factor beta signaling and triggers its degradation by the proteasome. J. Virol. 79 (2005) 4229-4237
11. Fujita T., Nolan G.P., Liou H.C., Scott M.L., and Baltimore D. The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-kappa B p50 homodimers. Genes Dev. 7 (1993) 1354-1363
12. Harris A.L. Hypoxia--a key regulatory factor in tumour growth. Nat. Rev. Cancer 2 (2002) 38-47
13. Hirota K., and Semenza G.L. Regulation of hypoxia-inducible factor 1 by prolyl and asparaginyl hydroxylases. Biochem. Biophys. Res. Commun. 338 (2005) 610-616
14. Hockel M., and Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 93 (2001) 266-276
15. Huang W.C., Ju T.K., Hung M.C., and Chen C.C. Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB. Mol. Cell 26 (2007) 75-87
16. Huibregtse J.M., Scheffner M., and Howley P.M. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J. 10 (1991) 4129-4135
17. Ikeda A., Sun X., Li Y., Zhang Y., Eckner R., Doi T.S., Takahashi T., Obata Y., Yoshioka K., and Yamamoto K. p300/CBP-dependent and -independent transcriptional interference between NF-kappaB RelA and p53. Biochem. Biophys. Res. Commun. 272 (2000) 375-379
18. Jiang M., and Milner J. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 21 (2002) 6041-6048
19. Jono H., Lim J.H., Chen L.F., Xu H., Trompouki E., Pan Z.K., Mosialos G., and Li J.D. NF-kappaB is essential for induction of CYLD, the negative regulator of NF-kappaB: evidence for a novel inducible autoregulatory feedback pathway. J. Biol. Chem. 279 (2004) 36171-36174
20. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 441 (2006) 431-436
21. Kawauchi K., Araki K., Tobiume K., and Tanaka N. Activated p53 induces NF-kappaB DNA binding but suppresses its transcriptional activation. Biochem. Biophys. Res. Commun. 372 (2008) 137-141
22. Kiyono T., Foster S.A., Koop J.I., McDougall J.K., Galloway D.A., and Klingelhutz A.J. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396 (1998) 84-88
23. Klingelhutz A.J., Foster S.A., and McDougall J.K. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 380 (1996) 79-82
24. Koong A.C., Chen E.Y., and Giaccia A.J. Hypoxia causes the activation of nuclear factor kappa B through the phosphorylation of I kappa B alpha on tyrosine residues. Cancer Res. 54 (1994) 1425-1430
25. Krappmann D., and Scheidereit C. A pervasive role of ubiquitin conjugation in activation and termination of IkappaB kinase pathways. EMBO Rep. 6 (2005) 321-326
26. Lando D., Peet D.J., Whelan D.A., Gorman J.J., and Whitelaw M.L. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295 (2002) 858-861
27. Le Q.T., Denko N.C., and Giaccia A.J. Hypoxic gene expression and metastasis. Cancer Metastasis Rev. 23 (2004) 293-310
28. Lee H.C., and Ziegler S.F. Inducible expression of the proallergic cytokine thymic stromal lymphopoietin in airway epithelial cells is controlled by NFkappaB. Proc. Natl. Acad. Sci. USA 104 (2007) 914-919
29. Linke S., Stojkoski C., Kewley R.J., Booker G.W., Whitelaw M.L., and Peet D.J. Substrate requirements of the oxygen-sensing asparaginyl hydroxylase factor-inhibiting hypoxia-inducible factor. J. Biol. Chem. 279 (2004) 14391-14397
30. Massoumi R., Chmielarska K., Hennecke K., Pfeifer A., and Fassler R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 125 (2006) 665-677
31. Mishra A., Bharti A.C., Varghese P., Saluja D., and Das B.C. Differential expression and activation of NF-kappaB family proteins during oral carcinogenesis: Role of high risk human papillomavirus infection. Int. J. Cancer 119 (2006) 2840-2850
32. Munger K., Baldwin A., Edwards K.M., Hayakawa H., Nguyen C.L., Owens M., Grace M., and Huh K. Mechanisms of human papillomavirus-induced oncogenesis. J. Virol. 78 (2004) 11451-11460
33. Nair A., Venkatraman M., Maliekal T.T., Nair B., and Karunagaran D. NF-kappaB is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix. Oncogene 22 (2003) 50-58
34. Narisawa-Saito M., Handa K., Yugawa T., Ohno S., Fujita M., and Kiyono T. HPV16 E6-mediated stabilization of ErbB2 in neoplastic transformation of human cervical keratinocytes. Oncogene 26 (2007) 2988-2996
35. Psyrri A., and DiMaio D. Human papillomavirus in cervical and head-and-neck cancer. Nat. Clin. Pract. Oncol. 5 (2008) 24-31
36. Reynolds T.Y., Rockwell S., and Glazer P.M. Genetic instability induced by the tumor microenvironment. Cancer Res. 56 (1996) 5754-5757
37. Royds J.A., Dower S.K., Qwarnstrom E.E., and Lewis C.E. Response of tumour cells to hypoxia: role of p53 and NFkB. Mol. Pathol. 51 (1998) 55-61
38. Ryan K.M., Ernst M.K., Rice N.R., and Vousden K.H. Role of NF-kappaB in p53-mediated programmed cell death. Nature 404 (2000) 892-897
39. Scheffner M., and Whitaker N.J. Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system. Semin. Cancer Biol. 13 (2003) 59-67
40. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., and Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63 (1990) 1129-1136
41. Scheffner M., Huibregtse J.M., Vierstra R.D., and Howley P.M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75 (1993) 495-505
42. Schofield C.J., and Ratcliffe P.J. Signalling hypoxia by HIF hydroxylases. Biochem. Biophys. Res. Commun. 338 (2005) 617-626
43. Subarsky P., and Hill R.P. The hypoxic tumour microenvironment and metastatic progression. Clin. Exp. Metastasis 20 (2003) 237-250
44. Tatum J.L., Kelloff G.J., Gillies R.J., Arbeit J.M., Brown J.M., Chao K.S., Chapman J.D., Eckelman W.C., Fyles A.W., Giaccia A.J., et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int. J. Radiat. Biol. 82 (2006) 699-757
45. Thomlinson R.H., and Gray L.H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer 9 (1955) 539-549
46. Vaupel P., Thews O., and Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med. Oncol. 18 (2001) 243-259
47. Vaupel P., Briest S., and Hockel M. Hypoxia in breast cancer: pathogenesis, characterization and biological/therapeutic implications. Wien. Med. Wochenschr. 152 (2002) 334-342
48. Wadgaonkar R., Phelps K.M., Haque Z., Williams A.J., Silverman E.S., and Collins T. CREB-binding protein is a nuclear integrator of nuclear factor-kappaB and p53 signaling. J. Biol. Chem. 274 (1999) 1879-1882
49. Waggoner S.E. Cervical cancer. Lancet 361 (2003) 2217-2225
50. Wang C., Deng L., Hong M., Akkaraju G.R., Inoue J., and Chen Z.J. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412 (2001) 346-351
51. Watanabe N., Iwamura T., Shinoda T., and Fujita T. Regulation of NFKB1 proteins by the candidate oncoprotein BCL-3: generation of NF-kappaB homodimers from the cytoplasmic pool of p50-p105 and nuclear translocation. EMBO J. 16 (1997) 3609-3620
52. Webster G.A., and Perkins N.D. Transcriptional cross talk between NF-kappaB and p53. Mol. Cell. Biol. 19 (1999) 3485-3495
53. Young S.D., Marshall R.S., and Hill R.P. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc. Natl. Acad. Sci. USA 85 (1988) 9533-9537